NUVL
Nuvalent, Inc. NASDAQ Listed Jul 29, 2021$102.48
Mkt Cap $7.5B
52w Low $63.55
78.7% of range
52w High $113.02
50d MA $101.81
200d MA $95.23
P/E (TTM)
-16.9x
EV/EBITDA
-672.4x
P/B
5.8x
Debt/Equity
0.0x
ROE
-34.1%
P/FCF
-26.6x
RSI (14)
—
ATR (14)
—
Beta
1.31
50d MA
$101.81
200d MA
$95.23
Avg Volume
564.9K
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
One Broadway · Cambridge, MA 02142 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 104.26 | -0.1% | -1.8% | — | — | — | — | — |
| Feb 26, 2026 | AMC | -1.48 | -1.29 | +12.8% | 103.93 | -0.9% | -1.9% | -2.5% | -3.6% | -1.2% | -3.7% | — |
| Oct 30, 2025 | AMC | -1.39 | -1.70 | -22.3% | 98.17 | +1.7% | +1.2% | -5.2% | -7.3% | -6.2% | -2.3% | — |
| Aug 7, 2025 | AMC | -1.27 | -1.31 | -3.1% | 72.16 | -0.2% | +2.7% | +3.9% | +6.2% | +8.4% | +6.4% | — |
| May 8, 2025 | AMC | -1.14 | -1.18 | -3.5% | 71.60 | +0.7% | -2.4% | +2.8% | -0.3% | -0.8% | -0.8% | — |
| Feb 27, 2025 | AMC | -1.04 | -1.05 | -1.0% | 74.91 | -1.2% | +0.1% | -5.2% | -4.4% | -3.9% | -2.6% | — |
| Nov 12, 2024 | AMC | -0.93 | -1.28 | -37.0% | 90.99 | +0.6% | -0.7% | -0.9% | -4.5% | -3.6% | +0.1% | — |
| Aug 8, 2024 | AMC | -0.76 | -0.88 | -15.8% | 70.24 | +0.2% | -0.4% | +2.7% | +1.7% | -0.3% | +2.4% | — |
| May 9, 2024 | AMC | -0.67 | -0.69 | -3.0% | 67.52 | -1.2% | -3.0% | -2.1% | +0.7% | +6.2% | +7.6% | — |
| Feb 27, 2024 | AMC | -0.59 | -0.62 | -5.1% | 88.99 | -0.3% | -4.1% | -5.5% | -2.0% | -4.5% | -8.5% | — |
| Nov 14, 2023 | AMC | -0.59 | -0.59 | +0.0% | 58.81 | -2.1% | +0.3% | -1.3% | +1.6% | +2.6% | +2.0% | — |
| Aug 10, 2023 | AMC | -0.53 | -0.51 | +3.8% | 43.48 | -1.2% | -1.0% | -1.3% | -3.0% | -3.6% | -5.5% | — |
| May 11, 2023 | AMC | -0.51 | -0.44 | +13.7% | 40.09 | +7.2% | -1.7% | +1.6% | -0.3% | -1.5% | -2.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $108.24 | $108.45 | +0.2% | -1.0% | +0.6% | -0.2% | -3.5% | -3.9% |
| Apr 8 | Wedbush | Maintains | Outperform → Outperform | — | $102.25 | $105.65 | +3.3% | +2.7% | +2.3% | +0.5% | +1.4% | +2.7% |
| Feb 27 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $103.93 | $102.96 | -0.9% | -1.9% | -2.5% | -3.6% | -1.2% | -3.7% |
| Dec 19 | JP Morgan | Maintains | Overweight → Overweight | — | $101.41 | $104.00 | +2.6% | +2.4% | +4.3% | +3.4% | +4.3% | +2.7% |
| Nov 18 | Baird | Maintains | Outperform → Outperform | — | $108.00 | $104.38 | -3.4% | -3.5% | -0.8% | +0.0% | -2.0% | +1.4% |
| Nov 18 | Guggenheim | Maintains | Buy → Buy | — | $108.00 | $104.38 | -3.4% | -3.5% | -0.8% | +0.0% | -2.0% | +1.4% |
| Nov 18 | Goldman Sachs | Maintains | Buy → Buy | — | $108.00 | $104.38 | -3.4% | -3.5% | -0.8% | +0.0% | -2.0% | +1.4% |
| Nov 17 | Stifel | Maintains | Buy → Buy | — | $96.50 | $93.30 | -3.3% | +11.9% | +8.0% | +11.0% | +11.9% | +9.7% |
| Nov 17 | Leerink Partners | Maintains | Outperform → Outperform | — | $96.50 | $93.30 | -3.3% | +11.9% | +8.0% | +11.0% | +11.9% | +9.7% |
| Nov 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $96.50 | $93.30 | -3.3% | +11.9% | +8.0% | +11.0% | +11.9% | +9.7% |
| Oct 31 | UBS | Maintains | Buy → Buy | — | $98.17 | $99.85 | +1.7% | +1.2% | -5.2% | -7.3% | -6.2% | -2.3% |
| Oct 31 | Barclays | Maintains | Overweight → Overweight | — | $98.17 | $99.85 | +1.7% | +1.2% | -5.2% | -7.3% | -6.2% | -2.3% |
| Oct 27 | Piper Sandler | Maintains | Overweight → Overweight | — | $93.39 | $94.95 | +1.7% | +4.6% | +8.4% | +10.3% | +5.1% | +6.3% |
| Sep 8 | Wedbush | Maintains | Outperform → Outperform | — | $80.89 | $80.77 | -0.1% | -1.3% | -2.7% | -3.0% | +1.6% | -0.5% |
| Jun 25 | Baird | Maintains | Outperform → Outperform | — | $76.88 | $77.60 | +0.9% | +2.9% | +2.9% | +3.6% | -0.8% | +1.5% |
| Jun 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $75.98 | $76.56 | +0.8% | +1.2% | +4.1% | +4.1% | +4.9% | +0.4% |
| Jun 24 | Leerink Partners | Maintains | Outperform → Outperform | — | $75.98 | $76.56 | +0.8% | +1.2% | +4.1% | +4.1% | +4.9% | +0.4% |
| Mar 14 | UBS | Upgrade | Neutral → Buy | — | $74.48 | $77.83 | +4.5% | +3.4% | +3.4% | +2.9% | +4.1% | +4.2% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $74.98 | $74.62 | -0.5% | -5.3% | -4.5% | -4.0% | -2.7% | -5.2% |
| Jan 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $75.99 | $76.53 | +0.7% | -0.2% | +3.0% | +7.0% | +10.1% | +8.2% |
| Nov 13 | BMO Capital | Maintains | Outperform → Outperform | — | $90.99 | $91.50 | +0.6% | -0.7% | -0.9% | -4.5% | -3.6% | +0.1% |
| Oct 4 | JP Morgan | Maintains | Overweight → Overweight | — | $103.50 | $105.27 | +1.7% | +1.4% | -0.1% | -1.1% | -2.2% | -1.0% |
| Sep 16 | BMO Capital | Maintains | Outperform → Outperform | — | $87.45 | $102.70 | +17.4% | +28.3% | +19.8% | +17.4% | +18.1% | +23.5% |
| Sep 16 | Wedbush | Maintains | Outperform → Outperform | — | $87.45 | $102.70 | +17.4% | +28.3% | +19.8% | +17.4% | +18.1% | +23.5% |
| Sep 16 | Stifel | Maintains | Buy → Buy | — | $87.45 | $102.70 | +17.4% | +28.3% | +19.8% | +17.4% | +18.1% | +23.5% |
| Sep 16 | Guggenheim | Maintains | Buy → Buy | — | $87.45 | $102.70 | +17.4% | +28.3% | +19.8% | +17.4% | +18.1% | +23.5% |
| Sep 9 | Wedbush | Maintains | Outperform → Outperform | — | $86.25 | $85.26 | -1.1% | +3.5% | +1.4% | -0.7% | -5.3% | +1.4% |
| Sep 4 | JP Morgan | Maintains | Overweight → Overweight | — | $83.64 | $83.08 | -0.7% | +1.1% | +1.6% | +3.1% | +6.7% | +4.6% |
| Jul 10 | Stifel | Maintains | Buy → Buy | — | $73.63 | $75.12 | +2.0% | +1.2% | +5.9% | +6.8% | +10.6% | +14.1% |
| May 17 | Wedbush | Maintains | Outperform → Outperform | — | $72.64 | $73.77 | +1.6% | -2.4% | -2.4% | -4.0% | -3.9% | -8.2% |
| Apr 1 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $75.09 | $77.14 | +2.7% | +2.7% | -2.2% | -1.5% | -4.2% | -6.5% |
| Mar 6 | JP Morgan | Maintains | Overweight → Overweight | — | $81.42 | $82.17 | +0.9% | +3.7% | +2.5% | +3.6% | +2.7% | +6.9% |
| Feb 28 | BMO Capital | Maintains | Outperform → Outperform | — | $88.99 | $88.74 | -0.3% | -4.1% | -5.5% | -2.0% | -4.5% | -8.5% |
| Oct 19 | BMO Capital | Maintains | Outperform → Outperform | — | $53.05 | $53.40 | +0.7% | -3.8% | -3.8% | -5.2% | -2.2% | -0.5% |
| Oct 5 | BMO Capital | Maintains | Outperform → Outperform | — | $57.51 | $58.35 | +1.5% | +8.5% | +12.2% | +8.5% | +6.9% | +6.4% |
| Oct 5 | JP Morgan | Maintains | Overweight → Overweight | — | $57.51 | $58.35 | +1.5% | +8.5% | +12.2% | +8.5% | +6.9% | +6.4% |
| Jul 20 | Wedbush | Maintains | Outperform → Outperform | — | $44.52 | $44.61 | +0.2% | +1.0% | +0.5% | +3.3% | +3.6% | +5.5% |
| Jun 23 | JP Morgan | Maintains | Overweight → Overweight | — | $42.07 | $42.12 | +0.1% | +4.2% | -2.2% | +1.3% | +1.9% | +1.8% |
| Jan 18 | Wedbush | Maintains | Outperform → Outperform | — | $33.30 | $34.66 | +4.1% | -0.9% | -1.7% | -7.3% | -7.3% | -1.8% |
| Jun 24 | BMO Capital | Maintains | Outperform → Outperform | — | $12.77 | $13.19 | +3.3% | +6.4% | +5.8% | +4.5% | +9.2% | +6.2% |
| Aug 23 | Cowen & Co. | Maintains | Outperform → Outperform | — | $27.02 | $27.46 | +1.6% | +7.3% | +9.6% | +14.5% | +21.2% | +28.4% |
| Aug 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $27.02 | $27.46 | +1.6% | +7.3% | +9.6% | +14.5% | +21.2% | +28.4% |
| Aug 23 | JP Morgan | Maintains | Overweight → Overweight | — | $27.02 | $27.46 | +1.6% | +7.3% | +9.6% | +14.5% | +21.2% | +28.4% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | Porter James Richard | President and CEO | Sell | 2,111 | $102.88 | $217K | 324,879 | -1.78% | — |
| May 4, 2026 | Porter James Richard | President and CEO | Sell | 17,353 | $102.10 | $1.8M | 326,990 | -1.78% | — |
| May 4, 2026 | Porter James Richard | President and CEO | Sell | 7,429 | $101.48 | $754K | 344,343 | -1.78% | — |
| May 4, 2026 | Porter James Richard | President and CEO | Sell | 1,408 | $99.77 | $140K | 351,772 | -1.78% | — |
| May 4, 2026 | Porter James Richard | President and CEO | Sell | 1,699 | $98.54 | $167K | 353,180 | -1.78% | — |
| May 1, 2026 | Balcom Alexandra | Chief Financial Officer | Sell | 124 | $99.97 | $12K | 85,533 | +2.75% | — |
| May 1, 2026 | Balcom Alexandra | Chief Financial Officer | Sell | 7,434 | $99.29 | $738K | 85,657 | +2.75% | — |
| May 1, 2026 | Balcom Alexandra | Chief Financial Officer | Sell | 3,872 | $98.42 | $381K | 93,091 | +2.75% | — |
| Apr 30, 2026 | Miller Deborah Ann | Chief Legal Officer | Sell | 1,082 | $99.57 | $108K | 59,634 | +3.61% | +6.30% |
| Apr 30, 2026 | Miller Deborah Ann | Chief Legal Officer | Sell | 4,418 | $99.13 | $438K | 60,716 | +3.61% | +6.30% |
| Apr 29, 2026 | Noci Darlene | Chief Development Officer | Sell | 300 | $101.17 | $30K | 58,117 | +3.61% | +6.30% |
| Apr 29, 2026 | Noci Darlene | Chief Development Officer | Sell | 700 | $100.14 | $70K | 58,417 | +3.61% | +6.30% |
| Apr 29, 2026 | Noci Darlene | Chief Development Officer | Sell | 4,500 | $99.35 | $447K | 59,117 | +3.61% | +6.30% |
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
I cannot provide a meaningful analysis because the filing content provided is incomplete—it contains only technical HTML/XML metadata without any actual material event details or substantive disclosure for Nuvei (NUVL).
Apr 7
8-K
Nuvalent, Inc. -- 8-K Filing
Nuvalent (NUVL) reported 2025 financial results and reaffirmed key pipeline milestones while advancing commercial preparations for potential U.S. product launches in its targeted cancer therapy programs.
Feb 26
Data updated apr 26, 2026 4:11pm
· Source: massive.com